Respiratory Syncytial Virus (RSV) Infections Pipeline Therapeutics Development Review H2 2015

Press Release   •   Dec 04, 2015 07:29 EST

This report provides comprehensive information on the therapeutic development for Respiratory Syncytial Virus (RSV) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Respiratory Syncytial Virus (RSV) Infections and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Complete report on H2, 2015 Pipeline Review of “Respiratory Syncytial Virus” addition with 79 market data tables and 15 figures: .

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from our proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by professional's team. Drug profiles/records featured in the report undergoes periodic updating following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Companies Discussed/Mentioned in this Research:

3-V Biosciences, Inc., Ablynx NV, ADMA Biologics, Inc., Agilvax, Inc., AmVac AG, Aridis Pharmaceuticals LLC, Artificial Cell Technologies, Inc., Astellas Pharma Inc., AstraZeneca Plc, Bavarian Nordic A/S, Biota Pharmaceuticals, Inc., Celltrion, Inc., Codagenix, Inc., Crucell N.V., CureVac GmbH, DBV Technologies S.A., Emergent BioSolutions Inc., Evec, Inc., F. Hoffmann-La Roche Ltd., Folia Biotech Inc., GenVec, Inc., Gilead Sciences, Inc., GlaxoSmithKline Plc, Globavir Biosciences, Inc., Humabs BioMed SA, iBio, Inc., ILiAD Biotechnologies, LLC, Immunovaccine, Inc., Johnson & Johnson, Kineta, Inc., mAbxience S.A., MedImmune, LLC, Medivir AB, Merck & Co., Inc., MSM Protein Technologies, Inc., Mucosis B.V., NanoBio Corporation, Navigen Pharmaceuticals, Inc., Novavax, Inc., Panacea Biotec Limited, Pulmocide Ltd, Regeneron Pharmaceuticals, Inc., Romark Laboratories, L.C., Sirnaomics, Inc., Spider Biotech, Spring Bank Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, TechnoVax, Inc., The International Biotechnology Center (IBC) Generium, Vaxart, Inc., VBI Vaccines Inc. and Virometix AG

Inquire before buying for this report . (This is a premium report price at US$2000 for a single user PDF license)

Drugs Profile Discussed in this Research:

AK-0529, ALS-8112, ALS-8176, ALX-0171, AMV-601, AMV-602, AMV-611, Antisense RNAi Oligonucleotide for Respiratory Syncytial Virus Infection, Antisense RNAi Oligonucleotides for RSV and Viral Respiratory Tract Infections, AR-201, AZ-27, BTAC-585, danirixin, DPX-RSV, EV-046120, EV-046135,GBV-006, GNR-007, GSK-3003891A, GSK-3389245A, GV-2311, GXV, human parainfluenza virus [type 1] + respiratory syncytial virus vaccine, influenza + RSV vaccine, JNJ-53718678, JNJ-61187165AAA, JNJ-61187191-AAA, MEDI-7510, MEDI-8897, Monoclonal Antibodies to Inhibit RSV-G and F Proteins for RSV Infections, Monoclonal Antibody for Respiratory Syncytial Virus, Monoclonal Antibody for RSV Infections, Monoclonal Antibody to Inhibit RSV-G and RSV-F for RSV Infections, MPE-8, MSM-605, MVA-RSV, nitazoxanide CR, palivizumab biosimilar, pertussis [strain BPZE1] vaccine, presatovir, Recombinant Protein for RSV Infections, REGN-2222, respiratory syncytial virus like particle vaccine, respiratory syncytial virus vaccine 1, respiratory syncytial virus vaccine 2, respiratory syncytical virus + influenza vaccine, RI-002, rOAS, RSV [strain 98-25147-X] vaccine, RSV vaccine, RSV-001, RV-521, SB-105A10, SB-9200, Small Molecule for RSV, Small Molecule to Agonize IRF-3 for Viral Infections, Small Molecules for Respiratory Syncitial Virus and Herpes Simplex Virus Infections, Small Molecules for Respiratory Syncytial Virus Infections, Small Molecules for RSV and Influenza A Infections, Small Molecules for RSV Infections, Small Molecules to Inhibit Respiratory Syncytial Virus Fusion Protein for RSV Infections, Small Molecules to Inhibit Viral RNA Polymerase for RSV Infections, STP-902, Synthetic Peptides to Inhibit RSV-F Protein for RSV Infection, TVB-3567, TVX-004IP and VMT-3


  • The report provides a snapshot of the global therapeutic landscape of Respiratory Syncytial Virus (RSV) Infections
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Respiratory Syncytial Virus (RSV) Infections and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Respiratory Syncytial Virus (RSV) Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Respiratory Syncytial Virus (RSV) Infections pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy:

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Respiratory Syncytial Virus (RSV) Infections
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Respiratory Syncytial Virus (RSV) Infections pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Explore More Research Report on Infectious Diseases therapeutics Market. is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries